Researchers

Name Executive director, Chief Technology Officer (Ph.D.)
Takaaki Ishii
Introduction of researchers Department of Applied Life Science, Faculty of Biology, Graduate school of Engineering, Sojo University, Doctor Course.
Division of Advanced Science and Biotechnology, Graduate School of Engineering, Osaka University.
Bio Process Systems Engineering, Graduate School of Engineering, Osaka University, Project Researcher (full time).
Start-up Cell Processing Center, Management and Education.
Activities in Academic Societies and Society. Member of the Japanese Society for Alternative Methods in Animal Experiments.
Member of the Japanese Society for Regenerative Medicine.
Member of the Japanese Society for Chemical Engineering.
Publications and Patents.
  1. T.Ishii, H.Saito, Y.Komizu, R.Tomoshige, and T.Matsushita.
    Effects of macroporous hydroxyapatite carriers on the growth and funtion of human hepatoblasts derived from fetal hepatocytes.
    J.Biosci Bioeng. 122(2):240-5.(2016)
  2. T.Ishii, H.Saito, Y.Komizu, R.Tomoshige, and T.Matsushita.
    Effects of the use of polyacrylonitrile nanofibers as 3D scaffolds on growth and function of human hepatoblasts derived from fetal hepatocytes. AATEX, 20, 66-72(2015)
  3. International Patent：CELL CULTURE MODULE, WO 2014/034146 A1

Name R&D Director (Ph.D.)
Tomoaki Inoue
Introduction of researchers Department of Biology, Faculty of Science, Kyushu University
Hoffman-La Roche Inc. (USA), Investigative Toxicology
Principal Scientist, Department of Toxicology, Nippon Roche Co., Ltd.
Later, merged with Chugai Pharmaceutical Co., Ltd.
Activities in Academic Societies and Society. Director of the Japanese Society of Immunotoxicology,
Councilor (Former Director) of the Japanese Society for Alternatives to Animal Experiments
Councilor of the Japanese Society of Toxicology
Member of the Testing Method Evaluation Committee in National Institutes of Health Sciences (Validation Management Team Member)
Leader of the Hepatocyte Team in the Consortium for Safety Assessment using Human iPS Cells
Publications and Patents.
  1. Human induced pluripotent stem cell-derived hepatocytes and their culturing methods to maintain liver functions for pharmacokinetics and safety evaluation of pharmaceuticals. T. Inoue, N. Iwazaki, T. Araki, H. Hitotsumachi, Curr. Pharm. Biotech., 21 (9), 773-779, 2020.
  2. Human induced pluripotent stem cell-derived mast cells useful for in vitro mast cell activation assay exhibiting phenotypes and morphological characteristics of human mast cells. T. Ikuno, S.Ito, T.Inoue,J. Toxicol. Sci.44 (11), 789 – 797, 2019.
  3. Requirements for human iPS cell derived hepatocytes as an alternative to primary human hepatocytes for assessing absorption, distribution, metabolism, excretion and toxicity of pharmaceuticals. T. Araki, N. Iwazaki, N. Ishiguro, , A. Sakamoto, K. Nagata, M. Ohbuchi, H. Moriguchi, M. Motoi, R. Shinkyo, T. Homma, S. Sakamoto, Y. Iwase, R. Ise, Y. Nakanishi, M. Uto, T. Inoue, Fund. Toxicol., 3 (3), 89-99, 2016.
  4. Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. M. Honda, J. Kiyokawa, M. Tabo, T. Inoue, J. Pharmacol. Sci., 117, 149-159, 2011.
  5. Application of human iPS cells to preclinical safety evaluation of drugs – Focusing on cardiotoxicity evaluation system -, T. Inoue, M. Honda, BIO Clinica, 26, 76-81, 2011.
  6. Safety evaluation of biopharmaceuticals, T. Inoue, K. Yasugi, Drug Delivery System, 26, 622-627, 2011.
  7. International Patent: Method for inducing differentiation of pluripotent stem cells into hepatocytes, PCT WO2019073951A1
  8. International Patent: Method for identifying epitope of protein, PCT WO2016010002A1
TOP